{
    "ticker": "IRWD",
    "name": "Ironwood Pharmaceuticals, Inc.",
    "description": "Ironwood Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for gastrointestinal (GI) diseases and disorders. Founded in 1998 and headquartered in Cambridge, Massachusetts, Ironwood focuses on the discovery and development of novel therapeutics that address unmet medical needs in the GI space. The company's flagship product, Linzess (linaclotide), is a prescription medication approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Linzess has become a leading treatment option, significantly improving the quality of life for patients suffering from these conditions. Ironwood's research pipeline continues to expand as the company invests in developing additional therapies for GI disorders, including its collaboration on new formulations and potential treatments for other gastrointestinal diseases. With a commitment to scientific excellence and patient-centric innovation, Ironwood is transforming the landscape of gastroenterology and striving to improve patient outcomes through its dedicated efforts in research and development. The company is well-positioned in the biopharmaceutical industry with a strong focus on advancing its pipeline and collaborations with other organizations to bring new therapies to market.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1998",
    "website": "https://www.ironwoodpharma.com",
    "ceo": "Mark E. Currie",
    "social_media": {
        "twitter": "https://twitter.com/IronwoodPharma",
        "linkedin": "https://www.linkedin.com/company/ironwood-pharmaceuticals/"
    },
    "investor_relations": "https://investors.ironwoodpharma.com",
    "key_executives": [
        {
            "name": "Mark E. Currie",
            "position": "CEO"
        },
        {
            "name": "Michael A. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gastrointestinal Drugs",
            "products": [
                "Linzess"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ironwood Pharmaceuticals, Inc. | Innovative GI Treatments",
        "meta_description": "Discover Ironwood Pharmaceuticals, Inc., focused on developing innovative treatments for gastrointestinal diseases. Learn about Linzess and our commitment to patient care.",
        "keywords": [
            "Ironwood Pharmaceuticals",
            "Gastrointestinal Drugs",
            "IBS-C Treatment",
            "Chronic Constipation",
            "Linzess"
        ]
    },
    "faq": [
        {
            "question": "What is Ironwood Pharmaceuticals known for?",
            "answer": "Ironwood Pharmaceuticals is known for developing treatments for gastrointestinal diseases, particularly its product Linzess."
        },
        {
            "question": "Who is the CEO of Ironwood Pharmaceuticals?",
            "answer": "Mark E. Currie is the CEO of Ironwood Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Ironwood headquartered?",
            "answer": "Ironwood is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is Linzess used for?",
            "answer": "Linzess is used for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC)."
        },
        {
            "question": "When was Ironwood Pharmaceuticals founded?",
            "answer": "Ironwood Pharmaceuticals was founded in 1998."
        }
    ],
    "competitors": [
        "ABBV",
        "AMGN",
        "BMY",
        "GILD"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "MRK",
        "AZN"
    ]
}